First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors
KHK2455 + mogamulizumab was safe and well tolerated with manageable toxicities, and resulted in dose-dependent suppression of IDO1 activity; signals of antitumor activity were observed.
Authors
- Akihiro Tokunaga
- Lisa H. Shiue
- Henry Zhao (ORCID: https://orcid.org/0000-0002-4320-4287)
- Solmaz Sahebjam (ORCID: https://orcid.org/0000-0001-9930-9937)
- David S. Hong (ORCID: https://orcid.org/0000-0001-8721-1609)
- Andreea Varga (ORCID: https://orcid.org/0000-0002-6395-9476)
- Capucine Baldini (ORCID: https://orcid.org/0000-0002-0604-7614)
- Sergey Efuni
- Yuta Ikawa
- Jameel Muzaffar (ORCID: https://orcid.org/0000-0003-1924-2301)
- Ursa Brown‐Glaberman
- Olivier Rixe (ORCID: https://orcid.org/0009-0005-7660-1739)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Emrullah Yilmaz (ORCID: https://orcid.org/0000-0003-2308-713X)
- Matthew Hruska (ORCID: https://orcid.org/0009-0000-8260-6003)
- Christophe Massard (ORCID: https://orcid.org/0000-0001-5505-0564)
- Yi Liu (ORCID: https://orcid.org/0000-0003-1635-4105)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of New Mexico (US)
- Kyowa Kirin (Japan) (JP)
- University of South Florida (US)
- Institut Gustave Roussy (FR)
- Moffitt Cancer Center (US)
- New Mexico Cancer Center (US)
- Kyowa Kirin (France) (FR)
- Kirin (United States) (US)
- UNM Comprehensive Cancer Center
Publication Details
- Journal
- Cancer
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1002/cncr.35939
- Citations
- 4
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.31
Funders
- Saitama Medical University